COMMUNIQUÉS West-GlobeNewswire

Invitation à assister à l'assemblée générale annuelle et extraordinaire des actionnaires de la Société qui se tiendra le 11 juin 2025
09/05/2025
INFORMATIONS RÉGLEMENTÉES le 9 mai 2025, 7:00h CET / 1:00h ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgique (ci-après la « Société ») Invitation à assister à l' [...]
Zealand Pharma announces closing of collaboration and license agreement with Roche
09/05/2025
Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
09/05/2025
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) , a biotechnology company historically focused on the development of a differentiated approach to [...]
Keros Reinforces Commitment to Maximizing Stockholder Value
08/05/2025
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- [...]
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
08/05/2025
-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed ® for first-line infertility treatment and FemBloc ® non-surgical permanent birth control (full system approval [...]
Nova Leap Health Corp. Posts Q1 2025 Results
08/05/2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 08, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
VitalHub Reports First Quarter 2025 Results
08/05/2025
Annual Recurring Revenue (ARR) ⁽¹⁾ up 54% YoY to $73.7 million Total Revenue up 42% YoY to $21.7 million Adjusted EBITDA ⁽¹⁾ up 39% YoY to $5.6 million TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the “ [...]
Tarsus to Participate in Upcoming Investor Conferences
08/05/2025
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America [...]
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
08/05/2025
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing [...]
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
08/05/2025
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO- [...]
BioSyent Schedules First Quarter Earnings Release for May 15, 2025
08/05/2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, [...]
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
08/05/2025
Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08 [...]
Galecto Reports First Quarter 2025 Operating and Financial Results
08/05/2025
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and [...]
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025
08/05/2025
MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based [...]
Theriva Biologics Announces Closing of $7.5 Million Public Offering
08/05/2025
ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related [...]
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
08/05/2025
On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025 Strengthened balance sheet with recent financing Advancing innovative POZ Platform across multiple [...]
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
08/05/2025
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its [...]
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
08/05/2025
Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 Nature Microbiology publication highlights preclinical data and the potential of CD388 as [...]
PacBio Announces First Quarter 2025 Financial Results
08/05/2025
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1 2024 Revenue $37.2 million $38.8 [...]

Pages